Earnings Call · Q4 FY2023·2024-02-20

Q4 23EPS -1.20%·Rev n/aQ3 23EPS +5.63%·Rev n/aQ2 23EPS +15.63%·Rev n/aQ1 23EPS -2.08%·Rev n/a⚠ consensus missing

HALOZYME THERAPEUTICS, INC. HALO

Tram Bui — Investor Relations

Helen Torley — Chief Executive Officer

Nicole LaBrosse — Chief Financial Officer

+6.6%1d on move date+6.5% vs SPY3d+12.7%5d+10.7%

Research tier

Behavioral profile computed for 3 speakers on this call.

Sign in to view the Behavioral Lean, the Behavioral Deviation Score, the speaker decomposition, and the novel forward-guidance phrases flagged on this call — each scored against the speaker's own prior-call baseline.

Behavioral data on every earnings call

Per-speaker language deviation, scored against each executive's own history. Explore more HALO calls or request research access.

More HALO calls Browse calls Request research access